Date: 2017-01-09
Type of information: Private placement
Company: Y-mAbs Therapeutics (USA - NY)
Investors:
Amount: $12 million
Funding type: private placement
Planned used:
- Y-mAbs Therapeutics is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. In addition, YmAbs utilizes its platform technologies to create next-generation humanized, affinity matured bispecific antibodies targeting GD2 and B7H3. This funding will enable YmAbs to focus on completing development and preparing the BLA for 131I-8H9 for refractory leptomeningeal metastasis from neuroblastoma.
Others:
- • On January 9, 2017, Y-mAbs Therapeutics announced that it has closed a private placement predominantly among its current shareholders raising $12 million. No placement agent was engaged in connection with the financing, which was oversubscribed.
Therapeutic area: Cancer - Oncology
Is general: Yes
